Metastatic pituitary tumors: an institutional case series
Authors' conclusion
Pituitary carcinomas are highly recurrent, heterogenous tumors with variable responses to treatment. Multidisciplinary management with an experienced neuro-endocrine and neuro-oncology team is needed given the unrelenting nature of this disease.
Study context
- Population
- Patients treated for pituitary carcinomas at one institution, 1992–2022; mean age at diagnosis 52.5 years (SD 19.4); most common subtype ACTH-producing pituitary adenomas (n = 12)
- Participants
- 14 patients
- Outcome
- Survival from pituitary adenoma diagnosis
Methodological detailssingle-institution, 30-year period (1992–2022), pooled analysis with literature cases
- Single-institution
- 30-year period (1992–2022)
- Pooled analysis with literature cases
Pooled result
As reported in the abstract
Median progression-free survival (PFS) from pituitary adenoma diagnosis
1.4 years
range 0.7–10.0
Median overall survival (OS) from pituitary adenoma diagnosis
8.4 years
range 2.3–24.0
Median PFS upon development of metastases
0.6 years
range 0.0–2.2
Median OS upon development of metastases
1.5 years
range 0.1–9.6
Further pooled results
Local invasion before metastasis (cavernous sinus, dorsum sellae dura or sphenoid sinus)
- Locally invasive disease prior to metastasis
- 12 patients
- Common metastatic sites: CNS, liver, lung, bone
Treatment of metastases with chemotherapy or radiation therapy plus chemotherapy (pooled analysis with literature cases)
- Significantly prolonged PFS
- P = 0.02
- No significant improvement in OS
- P = 0.14
- Pooled analysis including additional cases from the literature
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →